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A previously healthy 52-year old woman presented to the hospital with a 6-month history of progressive
dyspnea. Associated symptoms included a persistent dry cough that started 2 months prior admission
and an unintentional weight loss of 20 pounds over the course of her illness. On lung examination
revealed ﬁne bilateral end-inspiratory crackles in both lower and upper lobes. Radiographic studies
showed evidence of interstitial lung disease. The patient underwent bronchoscopy were transbronchial
biopsies were taken and showed ﬁbrosis of bronchial walls and lung parenchyma with prominent non-
necrotizing granulomata that contained abundant polarizing crystalline material. Once the pathologic
ﬁndings were known, the patient was re-interviewed. She reported that for the last 20-years, she used
baby talcum powder regularly at least twice a day, usually after bathing for personal hygiene. In addition,
she habitually applied it to her bed sheets nightly. She was started on prednisone at a dose of 0.5 mg/kg/
day, which was gradually tapered and then maintained on a dose of 5 mg daily. Her symptoms rapidly
improved over weeks to the point whereshe no longer required home oxygen therapy.
 2011 Elsevier Ltd. All rights reserved.1. History
A previously healthy 52-year old woman presented with a 6-
month history of progressive dyspnea, worsened to the point
where she was unable to perform daily activities. Associated
symptoms included a persistent dry cough that started 2 months
prior admission and an unintentional weight loss of 20 pounds over
the course of her illness. Denied fever, chills or night sweats. She
had a 20 pack-year of smoking and quit when the symptoms started
6 months before. She is a housewife with no outside occupations.
Her No family history was not signiﬁcant and she did not use
medications regularly.2. Physical examination
Normotensive, afebrile, with a heart rate of 106 anda respiratory
rate of 24 breaths/min. Pulse oximetry showed a 89% oxygen satu-
rationwhile breathing room air. Mild respiratory distress was noted
with use of accesory respiratory muscles. Lung examinationrank), jlascano@yahoo.com
rved.revealed ﬁne bilateral end-inspiratory crackles in both lower and
upper lobes. The restof the physical examinationwasunremarkable.3. Labaoratory ﬁndings
Complete blood count, and a comprehensive metabolic panel
were normal except for a mildly elevated bicarbonate level. Arterial
blood gas analysis showed a pH 7.44, pO2 67 mmHg and a pCO2
45 mmHg. A comprehensive rheumatologic panel was unremark-
able. Chest radiograph showed extensive bilateral parenchymal air
space and interstitial opacities (Fig. 1). High resolution computed
tomography (HRCT) scan showed bilateral symmetric airspace
opacities with central distribution affecting predominantly the
upper andmild lung ﬁelds. Multiple mediastinal lymph nodes were
noted (Fig. 2). Pulmonary function tests showed an FEV1 of 1.05 L
(34% predicted), a FEV1/FVC of 66% and a DLCO of 10.3 ml/mmHg/
min (42% predicted).
The patient underwent a bronchoscopy which disclosed
moderate airway edema without endobronchial lesions. Cytology
and microbiological studies of the bronchoalveolar lavage were
negative. Transbronchial biopsies showed ﬁbrosis of bronchial
walls and lung parenchyma with prominent non-necrotizing
granulomata that contained abundant polarizing crystalline
material (Figs. 3 and 4).
Fig. 1. Extensive bilateral parenchymal air space and intersticial opacities suggestive of
ﬁbrosis.
Fig. 3. Fibrotic Bronquial wall and lung tissue with prominent non-necrotizing gran-
ulomata containing abundant polarizable crystalline material (calcium oxalate/
magnesium silicate).
C. Frank, L. Jorge / Respiratory Medicine CME 4 (2011) 109e1111104. What is the diagnosis?
4.1. Diagnosis
Pulmonary Granulomatosis as a result of recurrent aspiration of
baby powder (Talcosis).5. Discussion
Intersticial lung diseases (ILD’s) are a heterogeneous group of
disorders that are classiﬁed together because of similar clinical,
radiological, physiologic, or pathologic manifestations. The enor-
mous differential diagnosis of interstitial lung disease can be made
manageable by understanding that pneumoconiosis, drug-induced
disease, and hypersensitivity pneumonitis account for over 80% of
the responsible entities and can usually be identiﬁed from the
patient’s history. The nine remaining diseases/disease categories
include: sarcoidosis, idiopathic pulmonary ﬁbrosis, bronchiolitis
obliterans-organizing pneumonia, histiocytosis X, chronic eosino-
philic pneumonia, collagen vascular disease-associated interstitial
lung disease, granulomatous vasculitis (Wegener’s granulomatosis,
Churg-Strauss syndrome, lymphomatoid granulomatosis), Good-
pasture’s syndrome, and pulmonary alveolar proteinosis. The inci-
dence of ILD is more common in males 31.5 per 100,000/year than
in females 26.1 per 100,000/year.
The pneumoconioses, interstitial lung disorders resulting from
the inhalation of organic dusts are the most common identiﬁableFig. 2. Prominent parahilar, parabronchovascular distribution of consolidation/opacity
with mid to upper lung zone distribution.causes of ILD and are related to occupational and environmental
exposures, also they are associated with chronic inﬂammatory
processes in the lower respiratory tract. Fibrosis of the alveolar
interstitium is a process common to all, the interstitial lung diseases
are distinguished by the presence of a chronic alveolitis that
produces a derangement of the alveolar structures and ultimately
leads to loss of functional gas exchange units (“end stage lung”).
The ﬁrst case of talc pneumoconiosis was reported by Thorel in
1896 and the ﬁrst fatal case due to massive aspiration of baby
powder in 1954 by Cless and Anger. There are only a few reports of
pulmonary talcosis associated with cosmetic talcum powder use.
Four different forms of pulmonary disease caused by talc have
been described three of them associated with inhalation: 1. Talc
associated with silica particles (talco-silicosis) presented in mine
workers, 2. asbesto ﬁbers (talco-asbestosis) associated with to
grinding and transportation of the product and 3. inhalation of
cosmetic talc (talcosis) a less common manifestation. The fourth
and more commonly seen disease associated with talc is caused by
endovenous administration of talc, particularly in intravenous drug
users.
The clinical manifestations of talcosis consist of dry cough and
chronic dyspnea that can progress to pulmonary ﬁbrosis, pulmo-
nary arterial hypertension, cor pulmonale and death. Delayed
hypersensitivity is the likely mechanism for the physiological andFig. 4. Polarized light reveals birefringent needle shaped particles in multinucleated
giant cells and macrofages.
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restrictive lung disease and often have diffuse bilateral intersticial
inﬁltrates. Histologically the lungs show peribronchiolar ﬁbrosis
with dust macules containing minute birefringence talc particles
asociated with multinucleated giant cells.
The pathophysiology of talcosis resembles that of sarcoidosis.
Talc granulomatosis is usually associated with high concentrations
of serum ACE and an increased number of lymphocytes in BAL. For
this reason, patient diagnosed with sarcoidosis should undergo
a detailed interview regarding exposure to organic or inorganic
dusts. Treatment with corticosteroids has been reported to be
associated with improvement of clinical symptoms and respiratory
function, although there is a risk of relapse after cessation.
Since there is considerable overlap in clinical features, imaging,
and laboratory ﬁndings between patients presenting with pulmo-
nary ﬁbrosis, a thorough history may provide the clincher to
a diagnosis. This case illustrates the importance of obtaining
a complete and detailed history, which should include environ-
mental exposures. Sometimes the historical information may be
obtained retrospectively as prompted by your diagnostic studies.
Who knew this common household product could lead to such an
uncommon hazard!
6. Clinical course
Once the pathologic ﬁndings were known, the patient was re-
interviewed. She reported that for the last 20-years, she used baby
talcum powder regularly at least twice a day, usually after bathing
for personal hygiene. In addition, she habitually applied it to her
bed sheets nightly.
The patient was advised to avoid any further talcum exposure
and she was started on prednisone at a dose of 0.5 mg/kg/day,
which was gradually tapered and then maintained on a dose of
5 mg daily. Her symptoms rapidly improved over weeks to the
point where she no longer required home oxygen therapy.
7. Clinical Pearls
1) Careful documentation of the past medical history is important
in the initial assessment because the cause of the illness is often
recognized from the patient’s history. Review of environmental
exposures at home and work environment, including that of
spouse and children, is invaluable.
2) The diagnosis of a speciﬁc interstitial lung disease can be made
via various means including the patient’s history, speciﬁc
serologies, bronchoalveolar lavage, transhronchial biopsy, and
biopsy of extrathoracic tissues or open lung biopsy.3) Overzealous application of baby powder can produce severe
pulmonary complications if the infant inspires the powder. On
the other hand, intravenous injection of ‘solubilized’, CNS
active pills can produce microemboli in small pulmonary
vessels. This can lead to various degrees of granuloma forma-
tion, compromised pulmonary function, or death.
4) Four distinct forms of pulmonary disease caused by talc have
been deﬁned. The ﬁrst form, talco-silicosis, is caused by talc
mined with high-silica-content mineral. Talco-asbestosis
closely resembles asbestosis and is produced by crystalline talc,
generally inhaled with asbestos ﬁbers. Pathologic and radio-
graphic abnormalities are virtually identical with those of
asbestosis, including calciﬁcations and malignant tumor
formation. The third form, talcosis, caused by inhalation of pure
talc, may include acute or chronic bronchitis as well as inter-
stitial inﬂammation. The fourth form and most common one,
due to intravenous administration of talc, is usually associated
with abuse of oral medications and production of vascular
granulomas manifested by consolidations, large nodules, and
masses.Conﬂict of interest
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